SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
- 17 July 2023
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 29 (8) , 2019-2029
Abstract
Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. After a dose-escalated phase 1 safety study, 90 participants were randomized to receive CoV-2-ST+SoC (n = 60) or SoC only (n = 30). The co-primary objectives of the study were the composite of time to recovery and 30-d recovery rate and the in vivo expansion of CoV-2-STs in patients receiving CoV-2-ST+SoC over SoC. The key secondary objective was survival on day 60. CoV-2-ST+SoC treatment was safe and well tolerated. The study met the primary composite endpoint (CoV-2-ST+SoC versus SoC: recovery rate 65% versus 38%, P = 0.017; median recovery time 11 d versus not reached, P = 0.052, respectively; rate ratio for recovery 1.71 (95% confidence interval 1.03–2.83, P = 0.036)) and the co-primary objective of significant CoV-2-ST expansion compared to SοC (CoV-2-ST+SoC versus SoC, P = 0.047). Overall, in hospitalized patients with severe COVID-19, adoptive immunotherapy with CoV-2-STs was feasible and safe. Larger trials are needed to strengthen the preliminary evidence of clinical benefit in severe COVID-19.Keywords
This publication has 54 references indexed in Scilit:
- T cells for viral infections after allogeneic hematopoietic stem cell transplantBlood, 2016
- Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infectionsBone Marrow Transplantation, 2016
- Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCTScience Translational Medicine, 2014
- Systemic Inflammatory Response Syndrome After Administration of Unmodified T LymphocytesMolecular Therapy, 2014
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantationBlood, 2013
- Memory CD4+ T cells protect against influenza through multiple synergizing mechanismsJournal of Clinical Investigation, 2012
- Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humansNature Medicine, 2012
- Expanding roles for CD4+ T cells in immunity to virusesNature Reviews Immunology, 2012
- Optimal sample sizes for phase II clinical trials and pilot studiesStatistics in Medicine, 2011
- Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experienceCytotherapy, 2010